Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Healthy Male and Female Caucasian and Male Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2014
At a glance
- Drugs JNJ 41443532 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 19 Mar 2012 Actual initiation date changed from Jul 2010 to May 2010 as reported by ClinicalTrials.gov.
- 16 Sep 2010 Actual end date added to 1 Aug 2010 as reported by ClinicalTrials.gov.
- 16 Sep 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.